Microglial Metabolic Reprogramming

Microglial Metabolic Reprogramming

Introduction

Microglial metabolic reprogramming refers to the dynamic shifts in cellular energy metabolism that microglia undergo in response to pathological stimuli in neurodegenerative diseases. This process involves a fundamental shift from oxidative phosphorylation (OXPHOS) in surveilling microglia to aerobic glycolysis in activated microglia, with profound implications for neuroinflammatory responses and disease progression [@yang2017].

Recent comprehensive reviews have synthesized the growing understanding of this phenomenon. A 2025 review in Molecular Neurobiology provides an updated synthesis of metabolic transitions from homeostasis to responsive states in microglia, highlighting metabolism-based targeted therapy approaches for neurodegeneration [@molneurobiol2025].

Metabolic States of Microglia

Homeostatic Microglia (OXPHOS-Dominant)

In the healthy brain, surveilling microglia rely primarily on oxidative phosphorylation for energy production. This metabolic state supports the sustained patrol and immune surveillance functions of homeostatic microglia. The mitochondria-dense cytoplasm enables efficient ATP production through the electron transport chain, with minimal glycolytic flux [Huang Y, et al. Metabolic reprogramming in microglia from Alzheimer's Disease brain. J Neuroinflammation. 2022;19(1):89](https://doi.org/10.1186/s12974-022-02456-2).

Activated Microglia (Glycolysis-Dominant)

Microglial Metabolic Reprogramming

Introduction

Microglial metabolic reprogramming refers to the dynamic shifts in cellular energy metabolism that microglia undergo in response to pathological stimuli in neurodegenerative diseases. This process involves a fundamental shift from oxidative phosphorylation (OXPHOS) in surveilling microglia to aerobic glycolysis in activated microglia, with profound implications for neuroinflammatory responses and disease progression [@yang2017].

Recent comprehensive reviews have synthesized the growing understanding of this phenomenon. A 2025 review in Molecular Neurobiology provides an updated synthesis of metabolic transitions from homeostasis to responsive states in microglia, highlighting metabolism-based targeted therapy approaches for neurodegeneration [@molneurobiol2025].

Metabolic States of Microglia

Homeostatic Microglia (OXPHOS-Dominant)

In the healthy brain, surveilling microglia rely primarily on oxidative phosphorylation for energy production. This metabolic state supports the sustained patrol and immune surveillance functions of homeostatic microglia. The mitochondria-dense cytoplasm enables efficient ATP production through the electron transport chain, with minimal glycolytic flux [Huang Y, et al. Metabolic reprogramming in microglia from Alzheimer's Disease brain. J Neuroinflammation. 2022;19(1):89](https://doi.org/10.1186/s12974-022-02456-2).

Activated Microglia (Glycolysis-Dominant)

Upon disease-related activation, microglia shift toward aerobic glycolysis [@huang2018]:

• Enhanced glucose uptake: Upregulation of glucose transporters (GLUT1/SLC2A1) increases glucose import 3-5 fold
• Elevated glycolytic enzymes: Hexokinase 2 (HK2), phosphofructokinase (PFK), and pyruvate kinase M2 (PKM2) are strongly upregulated
• Lactate production: Pyruvate is converted to lactate by LDH-A rather than entering the TCA cycle
• Pentose phosphate pathway: Increased flux through PPP generates NADPH for [oxidative-stress](/mechanisms/oxidative-stress) production and nucleotide biosynthesis
• Mitochondrial dysfunction: Progressive loss of mitochondrial membrane potential, reduced OXPHOS complex activity
• Pro-inflammatory phenotype: Glycolytic metabolism sustains [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome) activation and cytokine production

Metabolically Exhausted Microglia

In chronic neurodegeneration, sustained glycolytic activation leads to metabolic exhaustion: [@bernier2020]

• Energy crisis: Both OXPHOS and glycolysis become impaired, leading to ATP depletion
• Impaired phagocytosis: Loss of energy supply prevents effective clearance of amyloid plaques and debris
• Senescent phenotype: Metabolically exhausted [microglia](/cell-types/microglia) resemble senescent cells, with irreversible pro-inflammatory features
• Lipid accumulation: Failure of fatty acid oxidation drives lipid droplet accumulation, producing the LDAM phenotype

Molecular Regulators

mTOR-HIF-1α Axis

The mechanistic target of rapamycin ([mTOR](/mechanisms/mtor-neurodegeneration)) is a central metabolic sensor that drives the glycolytic switch in microglia [@masuch2016]:

• [TREM2](/proteins/trem2-protein)-[mTOR](/mechanisms/mtor-neurodegeneration) coupling: [TREM2](/proteins/trem2-protein) ligation by lipoproteins and [amyloid-beta](/proteins/amyloid-beta) activates PI3K-AKT-[mTOR](/mechanisms/mtor-neurodegeneration) signaling, increasing microglial metabolic capacity. [TREM2](/proteins/trem2-protein) loss-of-function variants (R47H, R62H) — which are Alzheimer's Disease risk factors — impair [mTOR](/mechanisms/mtor-neurodegeneration) activation, reducing both glycolytic and OXPHOS capacity and trapping microglia in a metabolically dysfunctional state [Ulland et al., 2017](https://doi.org/10.1016/j.cell.2017.07.023)
• HIF-1α stabilization: [mTOR](/mechanisms/mtor-neurodegeneration) activates hypoxia-inducible factor 1-alpha (HIF-1α), the master transcriptional regulator of glycolytic gene expression. HIF-1α upregulates GLUT1, HK2, LDHA, and PDK1 (which blocks pyruvate entry into mitochondria)
• Rapamycin effects: [mTOR](/mechanisms/mtor-neurodegeneration) inhibition by rapamycin reduces microglial glycolysis and inflammatory cytokine production, but also impairs beneficial [TREM2](/proteins/trem2-protein)-dependent responses, highlighting the dual nature of [mTOR](/entities/mtor) in neurodegeneration

AMPK Pathway

AMP-activated protein kinase (AMPK) is the counterregulator of [mTOR](/mechanisms/mtor-signaling-pathway) and promotes OXPHOS: [@zhang2019]

• Energy sensing: AMPK is activated by high AMP/ATP ratio, sensing energy depletion
• OXPHOS promotion: AMPK activates PGC-1α, promoting mitochondrial biogenesis and fatty acid oxidation
• Anti-inflammatory effects: AMPK activation suppresses NF-kappa-B signaling, reducing pro-inflammatory cytokine production
• Therapeutic potential: AMPK activators (metformin, AICAR) can restore microglial OXPHOS and reduce neuroinflammation in preclinical models

Glycolytic Enzymes as Regulators

Several glycolytic enzymes have moonlighting functions that directly regulate microglial inflammatory responses: [@latta2015]

• PKM2 (pyruvate kinase M2): In its dimeric form, PKM2 translocates to the nucleus and acts as a transcriptional coactivator for HIF-1α and STAT3, amplifying inflammatory gene expression. Pharmacological stabilization of PKM2 tetramers (using TEPP-46 or DASA-58) traps PKM2 in its enzymatic form, preventing nuclear translocation and reducing inflammation [Palsson-McDermott et al., 2015](https://doi.org/10.1016/j.cmet.2015.06.004)
• HK2 (hexokinase 2): Beyond its glycolytic role, HK2 interacts with VDAC on the mitochondrial outer membrane, regulating [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome) activation
• GAPDH: Undergoes post-translational modifications (succination, oxidation) in inflammatory microglia, affecting both glycolytic flux and gene regulation

Itaconate and the TCA Cycle

The TCA cycle intermediate itaconate has emerged as a key immunometabolite in microglia: [^9]

• Immune-responsive gene 1 (IRG1/ACOD1): Produces itaconate from cis-aconitate in the TCA cycle
• Anti-inflammatory effects: Itaconate inhibits succinate dehydrogenase (SDH), reducing succinate accumulation and HIF-1α stabilization
• Nrf2 activation: Dimethyl itaconate activates the [NRF2](/proteins/nrf2) antioxidant pathway, reducing oxidative damage
• Therapeutic potential: Itaconate derivatives are being explored as anti-inflammatory therapeutics for neurodegeneration

Disease-Specific Metabolic Alterations

Alzheimer's Disease

In [Alzheimer's Disease](/diseases/alzheimers-disease), microglial metabolic reprogramming occurs in stages:

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease):

• [Alpha-synuclein](/proteins/alpha-synuclein) fibrils activate microglial TLR2/4 signaling, triggering NF-κB-dependent glycolytic reprogramming
• [GBA](/proteins/gba-protein) mutations disrupt lysosomal-mitochondrial lipid trafficking, creating metabolic stress that promotes glycolytic shift
• [Dopamine](/entities/dopamine) depletion in the [substantia-nigra](/brain-regions/substantia-nigra) removes tonic inhibition of microglial activation, permitting metabolic reprogramming

ALS

In [ALS](/diseases/amyotrophic-lateral-sclerosis):

• [SOD1](/proteins/sod1) mutant protein in microglia induces [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) and oxidative damage, forcing glycolytic dependence
• [TDP-43](/proteins/tdp-43) pathology disrupts RNA processing of metabolic enzyme transcripts, altering the metabolic transcriptome
• Spinal cord microglia show progressive metabolic decline paralleling [motor neuron](/cell-types/motor-neurons) degeneration

Therapeutic Strategies

Metabolic Modulators

Several therapeutic approaches target microglial metabolism:

Mitochondrial-Targeted Approaches

• MitoQ and MitoTEMPO: Mitochondria-targeted antioxidants that reduce mitochondrial [oxidative-stress](/mechanisms/oxidative-stress) and preserve OXPHOS capacity
• Urolithin A: Activates [mitophagy](/mechanisms/mitophagy), clearing damaged mitochondria and promoting biogenesis of healthy organelles
• SS-31 (elamipretide): Stabilizes cardiolipin in the inner mitochondrial membrane, supporting electron transport chain function

Ketogenic and Dietary Approaches

• Ketone bodies: β-hydroxybutyrate (BHB) can serve as alternative fuel for microglial OXPHOS, bypassing glycolytic impairment. BHB also inhibits [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome) activation
• Ketogenic diet: Preclinical studies show reduced neuroinflammation and improved microglial function in AD models fed ketogenic diets
• Intermittent fasting: Enhances AMPK activation and mitophagy, potentially restoring microglial metabolic health

See Also

• [Oxidative Stress](/mechanisms/oxidative-stress)
• [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
• [mTOR in Neurodegeneration](/mechanisms/mtor-neurodegeneration)
• [TREM2](/proteins/trem2-protein)
• [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway)
• [NRF2](/proteins/nrf2)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GBA](/proteins/gba-protein)

References

Metabolic State Overview

| Metabolic State | Marker | Function | Disease Context |
|-----------------|--------|----------|-----------------|
| Glycolytic | HK2, PFKFB3 | Pro-inflammatory | Acute injury |
| OXPHOS | SDH, COX | Anti-inflammatory | Resolution |
| Hybrid | PKM2 | Intermediate | Chronic disease |